Iowa Mesothelioma Information

Iowa

While mesothelioma is a problem in all states, the specific incident rate for Iowa is 0.8 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in IA, recent IA mesothelioma-related court cases, mesothelioma specialists in IA and potential asbestos hotspots in Iowa.

[doptabs]
[doptab title=”Overview”]

Iowa Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of Iowa

Iowa Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

Iowa Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

Iowa Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

[/doptab]
[doptab title=”Treatment and Research”]

Research

[dopaccordions]
[dopaccordion title=”Donham, Kelley J. The Pathogenesis Of Asbestos Related Bowel Cancer
Grant: 1R26CA016762-01″ icon=27 activeicon=28]

Abstract: Workers exposed to asbestos have an increased incidence of bowel cancer as well as an increased incidence of lung cancer and mesothelioma. A pathologic study of a sample of asbestos-related bowel cancers revealed a very unusual type of chronic colitis underlying and apparently preceding the cancer. The proposal is to study asbestos cancers and precursor lesions in detail. Human material will be reviewed. In addition, the intestines of rats fed asbestos will be studied in detail to determine the full range and time sequence of asbestos-related pathology. Following this, the asbestos lesions will be studied as possible preferential sites for induction by known bowel carcinogens. 

Tags: Diseases, Pathologic Processes (not Classified Elsewhere), Gastrointestinal Neoplasms, Colon Growths, Neoplasms Of Gastrointestinal System, Colon Growths, Neoplastic Transformation, Carcinogens, Neoplastic Transformation, Carcinogens (general), Silicates, Asbestos Gastrointestinal Disorders, Enteritis, Colitis Human, Non-clinical, Human, Nonclinical*, Mammals, Rats* 

  • Followup Grant: 5R26CA016762-02
  • Followup Grant: 5R26CA016762-03
  • Followup Grant: 2R26CA016762-04

[/dopaccordion]
[/dopaccordions]

Clinical Trials

[dopaccordions]
[dopaccordion title=”Active, not recruiting Pemetrexed Disodium and Either Gemcitabine or Carboplatin in Treating Patients With Advanced Malignant Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: carboplatin;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Pazopanib in Treating Patients With Malignant Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: carboplatin;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium
More Information

[/dopaccordion]
[dopaccordion title=”Completed Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride;   Drug: gemcitabine hydrochloride
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Capecitabine in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
More Information

[/dopaccordion]
[dopaccordion title=”Completed Gefitinib in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: gefitinib
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: vatalanib
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting Collecting Tumor Samples From Patients With Gynecological Tumors” icon=27 activeicon=28][/dopaccordion]
[dopaccordion title=”” icon=27 activeicon=28]

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information

[/dopaccordion]
[/dopaccordions]
[/doptab]
[doptab title=”Doctors and Hospital”]

Hospital and Cancer Centers

Physicians

[/doptab]
[doptab title=”Cases”]

Cases

[/doptab]
[doptab title=”Lawyers”]

Lawyers

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

[contact-form-7 id=”372″ title=”Occupation”]
[/doptab]
[/doptabs]

Get your free copy of
Surviving Mesothelioma Today!